Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/29745
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18034/20233 (89%)
Visitors : 23744937      Online Users : 697
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/29745


    Title: Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44. is an indicator for recurrence in advanced cancer
    Authors: Wu, Cheng-Lin
    Chao, Ying-Jui
    Yang, Ta-Ming
    Chen, Yi-Ling
    Chang, Kung-Chao
    Hsu, Hui-Ping
    Shan, Yan-Shen
    Lai, Ming-Derg
    Contributors: 老人服務事業管理系
    Keywords: Ampullary cancer
    CD44
    CD44ν3-10
    CD44ν6-10
    Ingenuity pathway analysis
    Pancreatic invasion
    Date: 2015-11
    Issue Date: 2016-04-19 19:06:40 (UTC+8)
    Publisher: Biomed Central Ltd
    Abstract: Background: Although postoperative adjuvant chemoradiotherapies prevent recurrence for some patients with ampullary cancer, the recurrence rate is as high as 29 % in patients with stage I cancer. In an effort to identify predictors of recurrence in patients with ampullary adenocarcinoma, we investigated the clinical value of assessing standard and variant forms of CD44.
    Methods: Immunohistochemistry staining and reverse-transcription polymerase chain reaction (RT-PCR) was used to detect standard and variant forms of CD44 in samples of ampullary adenocarcinoma. The cDNA microarray analysis comparing tumors with or without pancreatic invasion was undertaken and analyzed by Ingenuity Pathway Analysis.
    Results: The standard CD44 (CD44s) isoform was detected in 76 of 98 patients with ampullary adenocarcinoma, and the negative or weak expression of CD44s was correlated with pancreatic invasion, lymphovascular invasion, advanced stage and bone metastasis. Moderate to dense expression of CD44s was correlated with shorter overall survival in patients with localized cancer (T1 or T2 disease, P = 0.0268). The patients with advanced cancer (T3 or T4 disease) and moderate or dense CD44s expression had a trend toward better survival. Alternative splicing of CD44 was confirmed using RT-PCR, which revealed that the CD44 nu 3-10 isoform was only expressed in patients with cancer recurrence. Fold change of CD44 nu 6-10 was also increased. In addition, networks containing CD44, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor-beta (TGF-beta), matrix metalloproteinase 2 (MMP2), AKT, extracellular signal-regulated protein kinase 1 and 2 (ERK1/2), p38 MAPK, activated protein 1 (AP1), and CTNNB1 were constructed after comparing microarray data from patients with and without pancreatic invasion.
    Conclusions: Whereas CD44s functions as tumor-promoting oncoprotein in early localized ampullary adenocarcinoma, CD44 variants are expressed in advanced cancer and patients with recurrence. Regional invasiveness and distant metastasis of ampullary cancer is controlled by a complex interacting network.
    Relation: BMC Cancer, v.15, Article ID 903
    Appears in Collections:[Dept. of Senior Service and Health Management] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML1641View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback